약사 국가시험: Free Mechanism, Quality and Practice Guide Study Guide

Apply it

An enzyme has Vmax 80 units and Km 4 micromolar. At 4 micromolar substrate, predict 40 units. At 12 micromolar, predict 60 units, assuming the simple model and unchanged enzyme concentration.

Apply it

A compound shifts the substrate concentration needed for half-maximal velocity from 3 to 9 micromolar, while both curves approach 120 units. Classify the pattern as competitive under the stated reversible steady-state assumptions.

Apply it

After adding an inhibitor, Vmax falls from 100 to 50 units and Km remains 5 micromolar. Pure noncompetitive inhibition fits. If Km also changes, examine mixed inhibition rather than preserving that label.

Apply it

An assay gives Km 8 micromolar and Vmax 96 units without inhibitor, then Km 4 micromolar and Vmax 48 units with inhibitor. The matched proportional decreases support a simple uncompetitive model.

Apply it

Two laboratories test the same reversible competitive inhibitor. One uses substrate near Km and the other uses substrate far above Km. A higher IC50 in the second laboratory can reflect substrate competition rather than compound degradation.

Apply it

A learner proposes amoxicillin for an isolated viral syndrome because viruses are infectious organisms. Explain that the relevant target is bacterial cell-wall biosynthesis, so infection alone does not establish a suitable target for this drug.

Apply it

An isolate is reported resistant to amoxicillin through beta-lactamase production. Interpret the result as bacterial inactivation of the antibiotic. Reassessing antibacterial selection is more rational than assuming that the patient failed to absorb every dose.

Apply it

A diagram shows reduced mevalonate formation followed by greater hepatic LDL uptake after rosuvastatin exposure. Link the first change to reductase inhibition and the second to increased LDL-receptor expression rather than direct LDL destruction in plasma.

Apply it

A vaccinated person later mounts a rapid response to the same antigen despite no recent antibody infusion. Explain the response through active immune memory rather than assuming that the original vaccine remained continuously present in circulation.

Apply it

An educational case requires immediate, temporary antibody protection before a recipient could generate a new response. Identify passive immunity as the relevant mechanism, while distinguishing it from a vaccine intended to stimulate longer-term active immunity.

Apply it

A report documents antigen-specific T-cell responses despite a modest measured antibody concentration. Recognize evidence of cell-mediated immunity instead of concluding that no adaptive response occurred merely because the humoral measurement was limited.

Apply it

A formulation contains a purified microbial surface antigen and no preformed antibody. If it stimulates the recipient’s own response, classify the resulting immunity as active even though the formulation contains no living microorganism.

Apply it

An adult with new hyperglycemia has findings supporting autoimmune destruction of insulin-producing pancreatic cells. Explain why adult age does not exclude type 1 diabetes and why the mechanism differs from simply having reduced insulin sensitivity.

Apply it

A person with type 1 diabetes develops vomiting and marked ketones during an infection. Connect the findings to insulin deficiency and increased fat-derived ketone production, and recognize the need for immediate medical assessment.

Apply it

Several people develop headache after using a fuel-burning heater indoors. One has conventional oxygen saturation of 99%. Treat the shared exposure as a major clue and seek urgent evaluation with appropriate carboxyhemoglobin testing.

Apply it

Over one year, an outcome occurs in 30 of 1,000 comparison participants and 10 of 1,000 intervention participants. Risks are 3% and 1%, giving an absolute reduction of 2 percentage points.

Apply it

An intervention lowers risk from 4% to 2%, while another population’s risk falls from 0.4% to 0.2%. Both show a 50% relative reduction, but absolute reductions are 2 and 0.2 percentage points.

Apply it

Two solutions both have pH 5. One contains a weak acid and its conjugate salt; the other is dilute strong acid adjusted to pH 5. Predict better resistance to a small base addition in the conjugate-pair solution.

Apply it

A hypothetical buffer has pKa 6.2, acid concentration 0.020 mol/L and conjugate-base concentration 0.060 mol/L. Calculate pH as 6.2 + log10(3), approximately 6.68, under the stated approximation.

Apply it

Two equal-volume buffers have the same acid-to-base ratio, but one contains ten times more of each component. Before adding an equal amount of strong acid, predict greater capacity for the more concentrated buffer.

Apply it

A mixture initially contains 10 mmol acid and 10 mmol conjugate base. Adding 2 mmol strong acid leaves 12 mmol acid and 8 mmol base. Use the resulting 8/12 ratio for the buffer calculation.

Apply it

Two mirror-image compounds show similar solubility in an achiral solvent but different receptor activity. Interpret the difference as compatible with stereoselective biological recognition rather than assuming that one sample must contain a different molecular formula.

Apply it

A development brief requires preferential formation of one enantiomer during the bond-forming reaction. A validated chiral-catalyst route addresses that requirement more directly than an achiral synthesis followed only by ordinary purification and total assay.

Apply it

Two lots each assay at 100 mg total compound. Chiral testing gives 99:1 and 70:30 enantiomer ratios. If the specification requires an enriched enantiomer, total content alone cannot establish equivalent lot quality.

Apply it

An assay gives the expected response for pure drug, but a degradation product contributes to the same unresolved signal. Challenge the method’s specificity before accepting stability samples whose apparent drug content may include that interferent.

Apply it

A 100-unit reference repeatedly measures 109, 110 and 110 units. The results cluster closely but are biased high. Investigate accuracy rather than treating the small spread as proof that the assay is fully suitable.

Apply it

An impurity signal is visible below the procedure’s demonstrated quantitation limit. Report it according to the method’s established rules rather than assigning an apparently exact concentration based only on an extrapolated calibration line.

Apply it

A chromatographic method repeats well, but a small deliberate mobile-phase change causes an impurity to overlap the analyte. The finding identifies robustness concerns and a need for tighter method controls or redevelopment.

Apply it

Two tablets break apart within the same interval but release different dissolved amounts in a validated test. Investigate formulation performance rather than declaring them equivalent solely because both tablets visibly disintegrated at similar times.

Apply it

A new lot appears to dissolve faster, but the laboratory also increased agitation. Repeat the comparison under the established common conditions before attributing the difference to a manufacturing improvement in the new formulation.

Apply it

Consider a hypothetical swallowed immediate-release tablet whose highest strength and maximum single dose are both 100 mg. This amount dissolves in no more than 200 mL throughout the required pH range at 37 ± 1°C. Its final dissolution sample is collected at 30 minutes, and the longest subsequent interval for sample preparation and chromatography is 90 minutes. Chemical-stability testing demonstrates stability in the dissolution medium for the full 120-minute period under the relevant handling conditions. The product is not narrow therapeutic index, its time to maximum concentration is not critical to efficacy, and its excipients and manufacturing history present no suitability concerns. It therefore meets these eligibility conditions. An otherwise identical tablet requiring 300 mL at pH 6.8 fails the solubility criterion; one stable for only 30 minutes fails the chemical-stability condition.

Apply it

Two suppliers use the same common plant name, but one supplies roots and the other leaves. Verify the botanical name and specified plant part before treating their materials as interchangeable inputs for one herbal preparation.

Apply it

A stable, readily measured constituent is chosen to compare herbal batches, but no contribution to therapeutic activity has been established. Describe it as an analytical marker rather than presenting its concentration as direct evidence of efficacy.

Apply it

In a hypothetical linear model, clearance falls from 8 to 4 L/hour with unchanged bioavailability and dose. Predict approximately doubled AUC, then identify exposure and drug-specific renal guidance as relevant to regimen review.

Apply it

A hypothetical drug’s clearance halves while distribution volume stays constant. Predict doubled half-life. Explain why maintaining the same long-term input may cause accumulation, while the initial amount needed for the same target concentration need not halve.

Apply it

A hypothetical adult has indexed eGFR 50 mL/min/1.73 m² and body surface area 2.08 m². The corresponding absolute estimate is about 60 mL/min. Use the value only within an appropriate drug-specific framework.

Apply it

A study reports similar total parent-drug AUC across renal groups, but an active metabolite accumulates substantially. Treat the parent result as incomplete evidence of unchanged pharmacological exposure rather than declaring the regimen equivalent.

Apply it

A patient asks whether one newly prescribed warfarin tablet immediately dissolves a clot. Explain its effect on production of functional vitamin K-dependent factors and why anticoagulant response and monitoring evolve over time.

Apply it

A patient with stable warfarin therapy receives a short antibiotic course. Arrange coordinated INR follow-up and interaction review at the medication transition rather than assuming that the short duration makes monitoring unnecessary.

Apply it

A patient plans to replace their usual diet with large daily servings of a vitamin K-rich drink. Identify the major intake change, discuss it with the anticoagulation team and coordinate INR monitoring rather than recommending abrupt unsupervised changes.

Apply it

A patient taking lisinopril begins a potassium-based salt substitute and already has impaired renal function. Identify the combined risk, review the product and arrange an appropriate potassium and renal-function assessment with the treating team.

Apply it

An older adult taking lisinopril and a diuretic develops vomiting and requests ibuprofen. Recognize volume depletion plus interacting medicines as a renal-risk combination and seek an appropriate analgesic and clinical assessment plan.

Apply it

A patient taking lisinopril reports new tongue swelling and difficulty swallowing. Direct immediate emergency care and no further lisinopril rather than arranging routine follow-up or treating the complaint as an expected mild adverse effect.

Apply it

A patient uses fluticasone-only HFA only when wheezing begins and expects immediate relief. Explain the maintenance role, review their prescribed rescue plan and arrange assessment if acute symptoms are not responding appropriately.

Apply it

A patient using fluticasone HFA demonstrates correct inhalation but swallows the rinse water afterward. Teach rinsing and spitting after the dose, explain the local-thrush rationale and ask the patient to demonstrate the corrected sequence.

Apply it

A patient actuates fluticasone HFA after finishing a rapid inhalation. Use the observed timing error to reteach coordinated actuation during a slow, deep breath, then verify the sequence through a second demonstration.

Apply it

For arithmetic practice, a verified order specifies 150 mg and the selected liquid contains 100 mg per 5 mL. The concentration is 20 mg/mL, so the measurable volume is 7.5 mL.

Apply it

A caregiver must measure 0.5 mL but receives a cup marked only in 5 mL intervals. Replace it with a suitably graduated oral device, retain the leading zero and verify the measured amount.

Apply it

A patient already taking naproxen buys an acetaminophen–ibuprofen combination for persistent pain. Identify ibuprofen as additional NSAID exposure and arrange a safer pain-management review rather than treating the combination as acetaminophen alone.

Apply it

An older patient using ibuprofen reports black tarry stools and new dizziness. Recognize possible bleeding and direct urgent medical evaluation rather than recommending an antacid or advising the patient merely to take future doses with food.

Apply it

A finished-product assay falls below its acceptance limit, and a repeat passes. Preserve both results, examine the original work promptly and determine whether a demonstrated assignable cause supports invalidation before making the batch decision.

Apply it

An investigation documents that the original sample was collected from an inappropriate location and was not representative. A justified resampling plan can address that defect, while retaining the original data and examining the sampling failure.

Apply it

Three batches pass a short accelerated study, but long-term observations are limited. Explain why assigning several years of shelf life solely from that pass would require unsupported extrapolation rather than an integrated stability evaluation.

Apply it

After explaining an oral-liquid regimen, say that you want to check your explanation and ask the caregiver to show the amount they will measure. Correct an observed misunderstanding and repeat the demonstration.

Apply it

A patient brings prescription tablets but leaves inhalers, pain remedies and supplements at home. Explain why those products matter and arrange a complete review before concluding that the recorded medication list captures current exposure.

Apply it

In a hypothetical pharmacy audit, 18 of 60 reviewed patients still have unresolved strength discrepancies despite receiving printed lists. The manager chooses appointment reminders to bring all containers, protected pharmacist reconciliation time and an assigned follow-up owner instead of spending the same resources on additional leaflets. For a patient taking both old and new strengths, the pharmacist confirms treatment intent with the prescriber, updates the list and verifies the next dose by demonstration. A subsequent comparable audit finds 6 of 60 unresolved cases: the observed rate fell from 30% to 10%, although this before-and-after comparison alone does not prove causation.

Apply it

A 38-year-old has confirmed autoimmune type 1 diabetes, persistent hyperglycemia and little endogenous insulin production. The patient is clinically stable without ketoacidosis and asks to choose between insulin treatment and metformin alone. Select insulin replacement because the decisive deficit is absent insulin production, rather than choosing oral monotherapy on the basis of adult age. Discuss injection or pump use and monitoring with the diabetes team. If vomiting and marked ketones develop, the immediate decision becomes emergency evaluation rather than routine outpatient treatment selection.

Apply it

A case explicitly states that a valid dispensing request was refused solely as a matter of personal preference, with no justifiable reason. Apply the statutory prohibition rather than inventing an unstated clinical or operational justification.

Apply it

A patient requests local pharmacy information, and clinic staff provide a comprehensive list of names and locations. Compare that response with routinely directing all prescription holders to one selected pharmacy under a preferential arrangement.

Apply it

A pharmacist provides a caregiver with necessary instructions in an understandable electronic counseling document. Recognize the permitted form, while checking that the content is suitable for the recipient rather than merely confirming that a file was sent.